Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd (CGEN) is a clinical-stage biotechnology company developing cancer immunotherapies through computational biology. The company's news typically covers clinical trial progress, partnership developments, and regulatory milestones related to its pipeline of immune checkpoint inhibitors discovered through AI-powered platforms.
For investors tracking Compugen, key news categories include updates on the company's lead programs COM701 and COM503 as they advance through clinical trials. Trial initiation announcements, patient dosing milestones, and interim efficacy data presentations at oncology conferences provide insight into the development trajectory of these novel antibodies. Partnership announcements and licensing agreements signal external validation of Compugen's computational discovery platform and can trigger milestone payments that impact the company's cash runway.
Compugen's quarterly earnings reports, filed as Form 6-K due to its foreign private issuer status, detail research and development spending, cash position, and progress across multiple clinical programs. These financial updates are particularly significant for clinical-stage biotechs, as they indicate how long the company can fund operations before requiring additional capital. Platform enhancement announcements, such as collaborations to integrate new sequencing technologies into the Unigen™ system, reflect the company's ongoing investment in its core computational capabilities.
News about partner-developed programs using Compugen-discovered targets, particularly rilvegostomig (formerly COM902), can affect the company's long-term royalty outlook even though Compugen is not directly conducting those trials. Conference presentations and peer-reviewed publications provide scientific validation of the company's approach to identifying immune regulatory mechanisms. Bookmark this page to track how Compugen's computational immunotherapy discovery model translates into clinical and commercial progress.
Compugen (Nasdaq: CGEN) announced its participation in the Stifel 2024 Healthcare Conference in New York City. The company's management will engage in a fireside chat scheduled for Monday, November 18, 2024, at 8:35 am ET. The event will be accessible through a live webcast on the Investor Relations section of Compugen's website, with a replay available after the event. Compugen, operating as a clinical-stage cancer immunotherapy company, is known for its pioneering work in computational target discovery.
Compugen (CGEN) has announced promising data on the triple combination of COM701, COM902, and pembrolizumab in treating platinum-resistant ovarian cancer patients. The data will be presented at the SITC 2024 conference in Houston, Texas. The study showed a 17.4% confirmed objective response rate and a 43.5% disease control rate in 23 evaluable patients.
The treatment demonstrated a favorable safety profile with mostly Grade 2 or lower adverse events, and only one Grade 3 event reported. Dr. Oladapo Yeku from Harvard Medical School highlighted the treatment's durability and effectiveness in late-stage ovarian cancer patients. The company plans to advance COM701 to earlier stages of ovarian cancer therapy, particularly targeting patients who are ineligible for maintenance treatment.
Daiichi Sankyo and AstraZeneca have initiated three global Phase 3 trials evaluating datopotamab deruxtecan (Dato-DXd) combinations in advanced nonsquamous non-small cell lung cancer (NSCLC). The trials include: TROPION-Lung10 testing Dato-DXd plus rilvegostomig in high PD-L1 expression patients; TROPION-Lung14 evaluating Dato-DXd plus osimertinib in EGFR mutated NSCLC; and TROPION-Lung15 studying Dato-DXd with/without osimertinib in EGFR mutated NSCLC that progressed on osimertinib. These trials are part of the expanding TROPION program, which now includes seven Phase 3 trials.
Compugen (Nasdaq: CGEN) announced it will release its Q3 2024 financial results on Tuesday, November 12, 2024, before U.S. markets open. The company will host a conference call and webcast at 8:30 AM ET to discuss financial results and provide a corporate update. Management will also discuss data presented at the Society for Immunotherapy of Cancer Annual Meeting (November 8-10, 2024). The conference call will be accessible via phone and live webcast through Compugen's website, with a replay available afterward.
Compugen (Nasdaq: CGEN) has announced that new clinical data will be presented at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 8-10, 2024. The presentation will focus on the anti-tumor activity and safety of a triple combination therapy involving COM701, COM902, and pembrolizumab in heavily pre-treated patients with platinum-resistant ovarian cancer.
The poster presentation, titled "Triple blockade of DNAM-1axis with COM701 (anti-PVRIG) + COM902 (anti-TIGIT) + pembrolizumab shows preliminary antitumor activity in patients with platinum resistant ovarian cancer, interim results of Phase I trial," will be delivered by Dr. Oladapo Yeku, a Medical Oncologist from Massachusetts General Hospital, on Friday, November 8, 2024. The abstract number for this presentation is 985.
Compugen (Nasdaq: CGEN) will present at the Single Cell Genomics 2024 conference in Greece from September 16-18, 2024. Dr. Roy Granit, Head of Computational Discovery, will showcase a poster on applying AI to gain insights into the novel immune checkpoint PVRIG through single-cell and spatial transcriptomics.
The presentation highlights additional biological insights generated using Compugen's AI/ML-powered computational discovery platform, UnigenTM. These findings support the potential of PVRIG inhibition to induce anti-tumor activity in indications previously resistant to immunotherapy, differentiating it from other immune checkpoints.
The poster presentation, titled 'Applying AI to Gain Insights into the Novel Immune Checkpoint PVRIG Through Single-Cell and Spatial Transcriptomics,' is scheduled for Monday, September 16, 2024. It will be available on Compugen's website following the presentation.
Compugen (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company, announced its upcoming virtual presentation at the H.C. Wainwright 26th Annual Global Investment Conference. The presentation will be available on-demand starting September 9, 2024, at 7:00 AM ET for 30 days on the company's Investor Relations website.
Compugen, known for its pioneering work in computational target discovery, aims to showcase its latest developments and strategies to investors and industry professionals. This presentation offers an opportunity for stakeholders to gain insights into Compugen's progress in the competitive field of cancer immunotherapy.
Compugen (CGEN) reported Q2 2024 results, highlighting key achievements and financial updates:
1. FDA clearance of COM503 IND triggered a $30 million milestone payment from Gilead.
2. On track to present data from COM701 + COM902 + pembrolizumab study in platinum-resistant ovarian cancer in Q4 2024.
3. AstraZeneca provided a non-risk adjusted peak year revenue target of over $5 billion for rilvegostomig, with Compugen eligible for future milestones and royalties.
4. Q2 2024 revenues: $6.7 million, compared to no revenues in Q2 2023.
5. Cash position: $92.3 million as of June 30, 2024, with runway expected to fund operations into 2027.
6. Net loss: $2.1 million ($0.02 per share) in Q2 2024, compared to $9.3 million ($0.11 per share) in Q2 2023.
Compugen (Nasdaq: CGEN) has received FDA clearance for its investigational new drug (IND) application for COM503, a potential first-in-class, high-affinity anti-IL-18 binding protein antibody for the treatment of solid tumors. This clearance triggers a $30 million milestone payment from Gilead Sciences, Inc., Compugen's licensing partner. The company is on track to initiate a Phase 1 trial for COM503 in Q4 2024.
COM503 represents a differentiated antibody approach to harness cytokine biology for cancer therapeutics, both as monotherapy and in combination treatments. This achievement strengthens Compugen's balance sheet, extending its expected cash runway into 2027. The company's preparation for the Phase 1 trial is well-advanced, showcasing its execution capabilities and diverse pipeline developed through its computational discovery engine.
Compugen (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and pioneer in computational target discovery, has announced the upcoming release of its second quarter 2024 financial results. The results will be disclosed on Tuesday, August 6, 2024, before the U.S. financial markets open. Following the release, the company's management will host a conference call and webcast at 8:30 AM ET to review the results and provide a corporate update.
Investors and interested parties can access the live conference call by dialing 1-866-744-5399 from the U.S. or +972-3-918-0644 internationally. Additionally, a live webcast will be available through Compugen's website. For those unable to attend the live event, a replay will be made available on the company's website following the webcast.
FAQ
What is the current stock price of Compugen (CGEN)?
What is the market cap of Compugen (CGEN)?
